Compare Invesco S&P 500 Momentum ETF (SPMO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 Momentum ETF vs TG Therapeutics Inc — how do they compare? Invesco S&P 500 Momentum ETF trades at $151.02, while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SPMO | TGTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $161.66 | $59.06 |
52-Week Low | $107.84 | $26.94 |
Market Cap | — | $7.64B |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPMO is trading at $151.21, up 1.69% with strong momentum characteristics. The ETF has demonstrated significant outperformance versus the S&P 500, gaining 26% year-to-date according to 24/7 Wall Street (2026-07-20). Technical indicators show a bullish trend with support at $147-148 and resistance at $149-151, though RSI levels suggest potential near-term consolidation.
The momentum-focused strategy continues to deliver alpha through concentrated technology exposure, particularly AI beneficiaries. However, high concentration risk and sector rotation vulnerability present challenges. With institutional interest growing and momentum factor dominance persisting, SPMO offers strategic exposure to market leaders but requires monitoring for momentum shifts.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
